AR104020A1 - Métodos y composiciones para inhibir la interacción de menina con proteínas mill - Google Patents
Métodos y composiciones para inhibir la interacción de menina con proteínas millInfo
- Publication number
- AR104020A1 AR104020A1 ARP160100689A ARP160100689A AR104020A1 AR 104020 A1 AR104020 A1 AR 104020A1 AR P160100689 A ARP160100689 A AR P160100689A AR P160100689 A ARP160100689 A AR P160100689A AR 104020 A1 AR104020 A1 AR 104020A1
- Authority
- AR
- Argentina
- Prior art keywords
- independently
- compound
- formula
- compositions
- heteroarylalkyl
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- 230000003993 interaction Effects 0.000 title abstract 2
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 6
- 101001045846 Homo sapiens Histone-lysine N-methyltransferase 2A Proteins 0.000 abstract 4
- 229910052760 oxygen Inorganic materials 0.000 abstract 4
- 229910052717 sulfur Inorganic materials 0.000 abstract 4
- 102100022103 Histone-lysine N-methyltransferase 2A Human genes 0.000 abstract 3
- 125000004429 atom Chemical group 0.000 abstract 3
- 125000004446 heteroarylalkyl group Chemical group 0.000 abstract 3
- 102100022102 Histone-lysine N-methyltransferase 2B Human genes 0.000 abstract 2
- 101001045848 Homo sapiens Histone-lysine N-methyltransferase 2B Proteins 0.000 abstract 2
- 101001008894 Homo sapiens Histone-lysine N-methyltransferase 2D Proteins 0.000 abstract 2
- 102100030550 Menin Human genes 0.000 abstract 2
- 101710169972 Menin Proteins 0.000 abstract 2
- 125000002252 acyl group Chemical group 0.000 abstract 2
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- 125000003282 alkyl amino group Chemical group 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 125000003368 amide group Chemical group 0.000 abstract 2
- 125000004103 aminoalkyl group Chemical group 0.000 abstract 2
- 125000001691 aryl alkyl amino group Chemical group 0.000 abstract 2
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 2
- 125000002102 aryl alkyloxo group Chemical group 0.000 abstract 2
- 125000001769 aryl amino group Chemical group 0.000 abstract 2
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 125000004104 aryloxy group Chemical group 0.000 abstract 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 2
- 125000000000 cycloalkoxy group Chemical group 0.000 abstract 2
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 abstract 2
- 125000006310 cycloalkyl amino group Chemical group 0.000 abstract 2
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 2
- 125000005112 cycloalkylalkoxy group Chemical group 0.000 abstract 2
- -1 cycloalkylalkylamino Chemical group 0.000 abstract 2
- 125000001188 haloalkyl group Chemical group 0.000 abstract 2
- 125000001475 halogen functional group Chemical group 0.000 abstract 2
- 125000004404 heteroalkyl group Chemical group 0.000 abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- 125000005241 heteroarylamino group Chemical group 0.000 abstract 2
- 125000005553 heteroaryloxy group Chemical group 0.000 abstract 2
- 125000000623 heterocyclic group Chemical group 0.000 abstract 2
- 125000004415 heterocyclylalkyl group Chemical group 0.000 abstract 2
- 125000005844 heterocyclyloxy group Chemical group 0.000 abstract 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 abstract 2
- 125000004043 oxo group Chemical group O=* 0.000 abstract 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 2
- 101150020251 NR13 gene Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 125000004450 alkenylene group Chemical group 0.000 abstract 1
- 125000006356 alkylene carbonyl group Chemical group 0.000 abstract 1
- 125000002947 alkylene group Chemical group 0.000 abstract 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 1
- IBAHLNWTOIHLKE-UHFFFAOYSA-N cyano cyanate Chemical compound N#COC#N IBAHLNWTOIHLKE-UHFFFAOYSA-N 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000004927 fusion Effects 0.000 abstract 1
- 102000037865 fusion proteins Human genes 0.000 abstract 1
- 108020001507 fusion proteins Proteins 0.000 abstract 1
- 125000004474 heteroalkylene group Chemical group 0.000 abstract 1
- 125000005114 heteroarylalkoxy group Chemical group 0.000 abstract 1
- 208000032839 leukemia Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Hydrogenated Pyridines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Priority Applications (25)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PT168038818T PT3303317T (pt) | 2015-06-04 | 2016-03-16 | Métodos e composições para inibição da interação de menina com proteínas llm |
| ES16803881T ES2902501T3 (es) | 2015-06-04 | 2016-03-16 | Métodos y composiciones para inhibir la interacción de menina con proteínas MLL |
| CA2985053A CA2985053C (en) | 2015-06-04 | 2016-03-16 | Methods and compositions for inhibiting the interaction of menin with mll proteins |
| KR1020187000217A KR102626673B1 (ko) | 2015-06-04 | 2016-03-16 | 메닌과 mll 단백질의 상호작용의 억제를 위한 방법 및 조성물 |
| CN202310178059.9A CN116217581A (zh) | 2015-06-04 | 2016-03-16 | 用于抑制多发性内分泌抑癌蛋白与mll蛋白质的相互作用的方法及组合物 |
| PCT/US2016/022717 WO2016195776A1 (en) | 2015-06-04 | 2016-03-16 | Methods and compositions for inhibiting the interaction of menin with mll proteins |
| DK16803881.8T DK3303317T3 (da) | 2015-06-04 | 2016-03-16 | Fremgangsmåder og sammensætninger til inhibering af interaktionen af menin med MLL-proteiner |
| CN201680046005.5A CN107922378A (zh) | 2015-06-04 | 2016-03-16 | 用于抑制多发性内分泌抑癌蛋白与mll蛋白质的相互作用的方法及组合物 |
| PH1/2017/502188A PH12017502188B1 (en) | 2015-06-04 | 2016-03-16 | Methods and compositions for inhibiting the interaction of menin with mll proteins |
| EP21193636.4A EP4006030A3 (en) | 2015-06-04 | 2016-03-16 | Methods and compositions for inhibiting the interaction of menin with mll proteins |
| BR112017026085-9A BR112017026085B1 (pt) | 2015-06-04 | 2016-03-16 | Métodos e composições para a inibição da interação da menin com proteínas da mll |
| PL16803881T PL3303317T3 (pl) | 2015-06-04 | 2016-03-16 | Sposoby i kompozycje do hamowania interakcji meniny z białkami mll |
| JP2017558557A JP6730321B2 (ja) | 2015-06-04 | 2016-03-16 | メニンとｍｌｌタンパク質との相互作用を阻害する方法及び組成物 |
| EA201792583A EA035141B1 (ru) | 2015-06-04 | 2016-03-16 | Способы и композиции для ингибирования взаимодействия менина с белками mll |
| MA043515A MA43515A (fr) | 2015-06-04 | 2016-03-16 | Méthodes et compositions d'inhibition de l'interaction de la ménine avec les protéines mll |
| HK18105970.3A HK1246298B (en) | 2015-06-04 | 2016-03-16 | Methods and compositions for inhibiting the interaction of menin with mll proteins |
| AU2016270002A AU2016270002B2 (en) | 2015-06-04 | 2016-03-16 | Methods and compositions for inhibiting the interaction of menin with MLL proteins |
| EP16803881.8A EP3303317B1 (en) | 2015-06-04 | 2016-03-16 | Methods and compositions for inhibiting the interaction of menin with mll proteins |
| NZ738015A NZ738015B2 (en) | 2016-03-16 | Methods and compositions for inhibiting the interaction of menin with mll proteins | |
| MX2017015467A MX382545B (es) | 2015-06-04 | 2016-03-16 | Metodos y composiciones para inhibir la interaccion de menina con proteinas de mll |
| IL255701A IL255701B (en) | 2015-06-04 | 2017-11-15 | Methods and preparations for inhibiting the interaction of menin with mll proteins |
| ZA2017/07848A ZA201707848B (en) | 2015-06-04 | 2017-11-20 | Methods and compositions for inhibiting the interaction of menin with mll proteins |
| US15/829,604 US10077271B2 (en) | 2015-06-04 | 2017-12-01 | Methods and compositions for inhibiting the interaction of menin with MLL proteins |
| US16/014,996 US10174041B2 (en) | 2015-06-04 | 2018-06-21 | Methods and compositions for inhibiting the interaction of menin with MLL proteins |
| US19/009,626 US20250304589A1 (en) | 2015-06-04 | 2025-01-03 | Methods and compositions for inhibiting the interaction of menin with mll proteins |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562171108P | 2015-06-04 | 2015-06-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR104020A1 true AR104020A1 (es) | 2017-06-21 |
Family
ID=58608916
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP160100689A AR104020A1 (es) | 2015-06-04 | 2016-03-15 | Métodos y composiciones para inhibir la interacción de menina con proteínas mill |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US10077271B2 (enExample) |
| EP (2) | EP4006030A3 (enExample) |
| JP (1) | JP6730321B2 (enExample) |
| KR (1) | KR102626673B1 (enExample) |
| CN (2) | CN107922378A (enExample) |
| AR (1) | AR104020A1 (enExample) |
| AU (1) | AU2016270002B2 (enExample) |
| CA (1) | CA2985053C (enExample) |
| DK (1) | DK3303317T3 (enExample) |
| EA (1) | EA035141B1 (enExample) |
| ES (1) | ES2902501T3 (enExample) |
| IL (1) | IL255701B (enExample) |
| MA (1) | MA43515A (enExample) |
| MX (1) | MX382545B (enExample) |
| MY (1) | MY186712A (enExample) |
| PH (1) | PH12017502188B1 (enExample) |
| PL (1) | PL3303317T3 (enExample) |
| PT (1) | PT3303317T (enExample) |
| TW (1) | TWI703150B (enExample) |
| WO (1) | WO2016195776A1 (enExample) |
| ZA (1) | ZA201707848B (enExample) |
Families Citing this family (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016040330A1 (en) | 2014-09-09 | 2016-03-17 | The Regents Of The University Of Michigan | Thienopyrimidine and thienopyridine compounds and methods of use thereof |
| AR104020A1 (es) | 2015-06-04 | 2017-06-21 | Kura Oncology Inc | Métodos y composiciones para inhibir la interacción de menina con proteínas mill |
| HK1246593A1 (zh) | 2015-06-04 | 2018-09-14 | Kura Oncology, Inc. | 用於抑制menin蛋白与mll蛋白的相互作用的方法及组合物 |
| BR112018068703B1 (pt) | 2016-03-16 | 2024-02-06 | Kura Oncology, Inc. | Inibidores substituídos de menin-mll e métodos de uso |
| KR102419524B1 (ko) | 2016-03-16 | 2022-07-08 | 쿠라 온콜로지, 인크. | 메닌-mll의 가교된 이환식 억제제 및 사용 방법 |
| WO2017192543A1 (en) | 2016-05-02 | 2017-11-09 | Regents Of The University Of Michigan | Piperidines as menin inhibitors |
| WO2017207387A1 (en) | 2016-05-31 | 2017-12-07 | Bayer Pharma Aktiengesellschaft | Spiro condensed azetidine derivatives as inhibitors of the menin-mml1 interaction |
| EA202092442A3 (ru) | 2016-06-07 | 2021-08-31 | Джакобио Фармасьютикалс Ко., Лтд. | Новые гетероциклические производные, применимые в качестве ингибиторов shp2 |
| US12084462B2 (en) | 2016-09-14 | 2024-09-10 | Janssen Pharmaceutica Nv | Spiro bicyclic inhibitors of menin-MLL interaction |
| BR112019004691A2 (pt) | 2016-09-14 | 2019-06-25 | Janssen Pharmaceutica Nv | inibidores bicíclicos em espiro da interação menina-mll |
| ES2966316T3 (es) | 2016-09-14 | 2024-04-19 | Janssen Pharmaceutica Nv | Inhibidores bicíclicos fusionados de interacción de MENIN-MLL |
| KR102513564B1 (ko) | 2016-12-15 | 2023-03-22 | 얀센 파마슈티카 엔.브이. | 메닌-mll 상호작용의 아제판 억제제 |
| EA201991448A1 (ru) | 2017-01-06 | 2019-12-30 | Янссен Фармацевтика Нв | Азепановые ингибиторы взаимодействия менин-mll |
| DK3604304T3 (da) * | 2017-03-23 | 2022-10-31 | Daegu Gyeongbuk Medical Innovation Found | Pyrrolo-pyridinderivatforbindelse, fremgangsmåde til fremstilling deraf og farmaceutisk sammensætning indeholdende denne som aktiv ingrediens til forebyggelse eller behandling af proteinkinase-relaterede sygdomme |
| AU2018239542C1 (en) | 2017-03-23 | 2021-02-11 | Jacobio Pharmaceuticals Co., Ltd. | Novel heterocyclic derivatives useful as SHP2 inhibitors |
| US11944627B2 (en) * | 2017-03-24 | 2024-04-02 | Kura Oncology, Inc. | Methods for treating hematological malignancies and Ewing's sarcoma |
| CA3058448A1 (en) | 2017-03-31 | 2018-10-04 | The Regents Of The University Of Michigan | Piperidines as covalent menin inhibitors |
| WO2018226976A1 (en) * | 2017-06-08 | 2018-12-13 | Kura Oncology, Inc. | Methods and compositions for inhibiting the interaction of menin with mll proteins |
| WO2018228923A1 (en) | 2017-06-13 | 2018-12-20 | Bayer Pharma Aktiengesellschaft | Substituted pyrrolopyridine-derivatives as map4k1 modulators for the treatment of cancer diseases |
| CA3066859A1 (en) | 2017-06-13 | 2018-12-20 | Bayer Pharma Aktiengesellschaft | Substituted pyrrolopyridine-derivatives |
| US20200246347A1 (en) | 2017-06-13 | 2020-08-06 | Bayer Pharma Aktiengesellschaft | Substituted Pyrrolopyridine-Derivatives |
| WO2019016071A1 (en) | 2017-07-18 | 2019-01-24 | Bayer Pharma Aktiengesellschaft | SUBSTITUTED PYRROLOPYRIDINE DERIVATIVES |
| WO2019060365A1 (en) | 2017-09-20 | 2019-03-28 | Kura Oncology, Inc. | SUBSTITUTED MÉNINE-MLL INHIBITORS AND METHODS OF USE |
| US11396517B1 (en) | 2017-12-20 | 2022-07-26 | Janssen Pharmaceutica Nv | Exo-aza spiro inhibitors of menin-MLL interaction |
| WO2019120209A1 (en) | 2017-12-20 | 2019-06-27 | Janssen Pharmaceutica Nv | Exo-aza spiro inhibitors of menin-mll interaction |
| WO2019160882A1 (en) | 2018-02-13 | 2019-08-22 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
| US11325921B2 (en) | 2018-03-30 | 2022-05-10 | Sumitomo Dainippon Pharma Co., Ltd. | Optically active crosslinked cyclic secondary amine derivative |
| WO2019204609A1 (en) | 2018-04-19 | 2019-10-24 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
| BR112020026746A2 (pt) | 2018-07-13 | 2021-03-30 | Gilead Sciences, Inc. | Composto, composição farmacêutica, métodos para inibir pd-1, pd-l1 e/ou a interação de pd-1/pd-l1 e para tratar câncer, e, kit para tratar ou prevenir câncer ou uma doença ou condição. |
| US20210393623A1 (en) | 2018-09-26 | 2021-12-23 | Jacobio Pharmaceuticals Co., Ltd. | Novel Heterocyclic Derivatives Useful as SHP2 Inhibitors |
| CN113164443A (zh) * | 2018-09-26 | 2021-07-23 | 库拉肿瘤学公司 | 用多发性内分泌抑癌蛋白抑制剂治疗血液系统恶性肿瘤 |
| CN112955435B (zh) | 2018-10-24 | 2024-09-06 | 吉利德科学公司 | Pd-1/pd-l1抑制剂 |
| BR112021007421A2 (pt) * | 2018-12-06 | 2021-08-03 | Daiichi Sankyo Company, Limited | derivado de cicloalcano-1,3-diamina |
| US20220047603A1 (en) | 2018-12-11 | 2022-02-17 | Bayer Aktiengesellschaft | Substituted pyrrolopyridine-derivatives |
| EP3915985A4 (en) | 2019-01-18 | 2022-09-28 | Voronoi Co., Ltd. | PYRROLOPYRIDE DERIVATIVE AND USE THEREOF FOR THE PREVENTION AND TREATMENT OF PROTEIN KINASE RELATED DISEASES |
| ES2987269T3 (es) * | 2019-09-20 | 2024-11-14 | Novartis Ag | Inhibidores de MLL1 y agentes anticancerígenos |
| CN118255773A (zh) | 2019-12-19 | 2024-06-28 | 詹森药业有限公司 | 取代的直链螺环衍生物 |
| BR112022024729A2 (pt) | 2020-06-05 | 2023-02-28 | Kinnate Biopharma Inc | Inibidores de quinases do receptor do fator de crescimento de fibroblastos |
| WO2021249913A1 (en) | 2020-06-09 | 2021-12-16 | Bayer Aktiengesellschaft | 2'-(quinolin-3-yl)-5',6'-dihydrospiro[azetidine-3,4'-pyrrolo[1,2-b]pyrazole]-1-carboxylate derivatives and related compounds as map4k1 (hpk1) inhibitors for the treatment of cancer |
| US20230405008A1 (en) * | 2020-10-21 | 2023-12-21 | Kura Oncology, Inc. | Treatment of hematological malignancies with inhibitors of menin |
| CN114516873A (zh) * | 2020-11-18 | 2022-05-20 | 苏州优理生物医药科技有限公司 | 一种螺环类化合物、包含其药物组合物及其应用 |
| KR20220081631A (ko) | 2020-12-09 | 2022-06-16 | 보로노이 주식회사 | 염증성 질환의 예방 및/또는 치료를 위한 피롤로-피리딘 유도체 화합물의 신규 용도 |
| CN116964050A (zh) * | 2020-12-16 | 2023-10-27 | 戈萨默生物服务公司 | 可用作t细胞激活剂的化合物 |
| WO2022167627A1 (en) | 2021-02-05 | 2022-08-11 | Bayer Aktiengesellschaft | Map4k1 inhibitors |
| US12037346B2 (en) | 2021-04-13 | 2024-07-16 | Nuvalent, Inc. | Amino-substituted heteroaryls for treating cancers with EGFR mutations |
| KR20240005747A (ko) | 2021-05-08 | 2024-01-12 | 얀센 파마슈티카 엔브이 | 치환된 스피로 유도체 |
| CA3215379A1 (en) | 2021-05-08 | 2022-11-17 | Olivier Alexis Georges Querolle | Substituted spiro derivatives |
| JP2024521879A (ja) | 2021-06-01 | 2024-06-04 | ヤンセン ファーマシューティカ エヌ．ベー． | 置換フェニル－１Ｈ－ピロロ［２，３－ｃ］ピリジン誘導体 |
| BR112023025436A2 (pt) | 2021-06-03 | 2024-02-27 | Janssen Pharmaceutica Nv | Piridazinas ou 1,2,4-triazinas substituídas por aminas espirocíclicas |
| JP2024525145A (ja) | 2021-06-17 | 2024-07-10 | ヤンセン ファーマシューティカ エヌ．ベー． | がんなどの疾患の治療のための（ｒ）－ｎ－エチル－５－フルオロ－ｎ－イソプロピル－２－（（５－（２－（６－（（２－メトキシエチル）（メチル）アミノ）－２－メチルヘキサン－３－イル）－２，６－ジアザスピロ［３．４］オクタン－６－イル）－１，２，４－トリアジン－６－イル）オキシ）ベンズアミドベシル酸塩 |
| WO2023011446A1 (zh) * | 2021-08-04 | 2023-02-09 | 成都苑东生物制药股份有限公司 | 一种新型磺酰胺类menin-MLL相互作用抑制剂、其制备方法及医药用途 |
| CN115515958B (zh) * | 2021-08-04 | 2023-09-29 | 成都苑东生物制药股份有限公司 | 一种新型磺酰胺类menin-MLL相互作用抑制剂、其制备方法及医药用途 |
| WO2023107705A1 (en) | 2021-12-10 | 2023-06-15 | Incyte Corporation | Bicyclic amines as cdk12 inhibitors |
| EP4554579A2 (en) * | 2022-07-14 | 2025-05-21 | Huyabio International, LLC | Combination therapies of wdr5 inhibitors and pd-1 inhibitors |
| CN120529900A (zh) | 2022-11-24 | 2025-08-22 | 奥莱松基因组股份有限公司 | 用于治疗癌症的LSD1抑制剂和Menin抑制剂的组合 |
| WO2025019497A2 (en) | 2023-07-17 | 2025-01-23 | Kura Oncology, Inc. | Crystalline forms of a menin inhibitor |
| TW202517650A (zh) | 2023-07-17 | 2025-05-01 | 美商庫拉腫瘤技術股份有限公司 | 包含ｍｅｎｉｎ抑制劑之醫藥組合物 |
| WO2025044946A1 (zh) * | 2023-08-25 | 2025-03-06 | 武汉人福创新药物研发中心有限公司 | 作为mrgprx2拮抗剂的化合物及其制备方法和应用 |
| WO2025232874A1 (en) * | 2024-05-10 | 2025-11-13 | Kura Oncology, Inc. | Process of making a menin-mll inhibitor |
Family Cites Families (78)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5863A (en) | 1848-10-17 | Matthias p | ||
| US5861A (en) | 1848-10-17 | Locking umbrella and parasol | ||
| US510A (en) | 1837-12-07 | soeel | ||
| US949A (en) | 1838-09-27 | Improvement in roller cotton-gins for ginning long-staple and other kinds of cotton | ||
| US5052558A (en) | 1987-12-23 | 1991-10-01 | Entravision, Inc. | Packaged pharmaceutical product |
| US5033252A (en) | 1987-12-23 | 1991-07-23 | Entravision, Inc. | Method of packaging and sterilizing a pharmaceutical product |
| GB8827305D0 (en) | 1988-11-23 | 1988-12-29 | British Bio Technology | Compounds |
| US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
| US5455258A (en) | 1993-01-06 | 1995-10-03 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamic acids |
| US5863949A (en) | 1995-03-08 | 1999-01-26 | Pfizer Inc | Arylsulfonylamino hydroxamic acid derivatives |
| DK0821671T3 (da) | 1995-04-20 | 2001-04-23 | Pfizer | Arylsulfonylhydroxamsyrederivater som MMP- og TNF-inhibitorer |
| ES2183905T3 (es) | 1995-12-20 | 2003-04-01 | Hoffmann La Roche | Inhibidores de metaloproteasa de matriz. |
| JP3195756B2 (ja) | 1996-07-04 | 2001-08-06 | 公子 吉水 | 潤滑補助体 |
| HUP9903014A3 (en) | 1996-07-18 | 2000-08-28 | Pfizer | Phosphinate derivatives having matrix metalloprotease inhibitor effect and medicaments containing the same |
| US6153609A (en) | 1996-08-23 | 2000-11-28 | Pfizer Inc | Arylsulfonylamino hydroxamic acid derivatives |
| AU5131998A (en) | 1997-01-06 | 1998-08-03 | Pfizer Inc. | Cyclic sulfone derivatives |
| ES2202796T3 (es) | 1997-02-03 | 2004-04-01 | Pfizer Products Inc. | Derivados de acidos arilsulfonilaminohidroxamicos. |
| JP2000507975A (ja) | 1997-02-07 | 2000-06-27 | ファイザー・インク | Ｎ−ヒドロキシ−β−スルホニルプロピオンアミド誘導体類及びそれらのマトリックスメタロプロテイナーゼ阻害薬としての使用 |
| BR9807678A (pt) | 1997-02-11 | 2000-02-15 | Pfizer | Derivados de ácidos arilsulfonil-hidroxâmicos |
| JPH10330377A (ja) | 1997-06-02 | 1998-12-15 | Kyowa Hakko Kogyo Co Ltd | ピペリジン誘導体 |
| GB9725782D0 (en) | 1997-12-05 | 1998-02-04 | Pfizer Ltd | Therapeutic agents |
| GB9801690D0 (en) | 1998-01-27 | 1998-03-25 | Pfizer Ltd | Therapeutic agents |
| US6479487B1 (en) * | 1998-02-26 | 2002-11-12 | Aventis Pharmaceuticals Inc. | 6, 9-disubstituted 2-[trans-(4-aminocyclohexyl)amino] purines |
| PA8469501A1 (es) | 1998-04-10 | 2000-09-29 | Pfizer Prod Inc | Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico |
| PA8469401A1 (es) | 1998-04-10 | 2000-05-24 | Pfizer Prod Inc | Derivados biciclicos del acido hidroxamico |
| PA8474101A1 (es) | 1998-06-19 | 2000-09-29 | Pfizer Prod Inc | Compuestos de pirrolo [2,3-d] pirimidina |
| DE60227794D1 (de) | 2001-04-26 | 2008-09-04 | Eisai R&D Man Co Ltd | Stickstoffhaltige verbindung mit kondensiertem ring und pyrazolylgruppe als substituent und medizinische zusammensetzung davon |
| US6849638B2 (en) | 2001-04-30 | 2005-02-01 | Bayer Pharmaceuticals Corporation | 4-amino-5,6-substituted thiopheno [2,3-d] pyrimidines, pharmaceutical compositions containing the same, and their use in the treatment or prevention of pde7b-mediated diseases and conditions |
| US7115741B2 (en) | 2001-09-06 | 2006-10-03 | Levy Daniel E | 4-thieno[2,3-D]pyrimidin-4-YL piperazine compounds |
| AU2003258662A1 (en) | 2002-10-02 | 2004-04-23 | Merck Patent Gmbh | Use of 4-amino-quinazolines as anti cancer agents |
| AU2003255482A1 (en) | 2002-10-02 | 2004-04-23 | Merck Patent Gmbh | Use of 4 amino-quinazolines as anti cancer agents |
| US7612078B2 (en) * | 2003-03-31 | 2009-11-03 | Epix Delaware, Inc. | Piperidinylamino-thieno[2,3-D] pyrimidine compounds |
| US20050222175A1 (en) | 2004-03-31 | 2005-10-06 | Dhanoa Dale S | New piperidinylamino-thieno[2,3-D] pyrimidine compounds |
| WO2004089312A2 (en) | 2003-03-31 | 2004-10-21 | Predix Pharmaceuticals Holdings, Inc. | New piperidinylamino-thieno[2,3-d] pyrimidine compounds |
| WO2005020897A2 (en) | 2003-08-22 | 2005-03-10 | Dendreon Corporation | Compositions and methods for the treatment of disease associated with trp-p8 expression |
| US20050123906A1 (en) | 2003-11-06 | 2005-06-09 | Rana Tariq M. | Protein modulation |
| EP1768964A1 (en) | 2004-07-06 | 2007-04-04 | Angion Biomedica Corporation | Quinazoline modulators of hepatocyte growth factor / c-met activity for the treatment of cancer |
| MX2007015165A (es) | 2005-06-03 | 2008-02-14 | Abbott Lab | Derivados de ciclobutil-amina. |
| US20060281769A1 (en) | 2005-06-10 | 2006-12-14 | Baumann Christian A | Synergistic modulation of flt3 kinase using thienopyrimidine and thienopyridine kinase modulators |
| US20060281771A1 (en) | 2005-06-10 | 2006-12-14 | Baumann Christian A | Synergistic modulation of flt3 kinase using aminoquinoline and aminoquinazoline kinase modulators |
| BRPI0615922A2 (pt) | 2005-09-02 | 2011-05-31 | Tibotec Pharm Ltd | benzodiazepinas como inibidores de hcv |
| CN101466716A (zh) | 2006-04-07 | 2009-06-24 | 德维洛根股份公司 | 用于药物组合物的具有mnkl/mnk2抑制活性的噻吩并嘧啶 |
| WO2008070303A2 (en) | 2006-10-19 | 2008-06-12 | The University Of Chicago | Therapeutics to inhibit mll-menin interaction for treating leukemia |
| EP1947103A1 (en) | 2007-01-22 | 2008-07-23 | 4Sc Ag | Aryloxypropanolamines, methods of preparation thereof and use of aryloxypropanolamines as medicaments |
| WO2008099019A1 (en) | 2007-02-16 | 2008-08-21 | Tibotec Pharmaceuticals Ltd. | 6-hydroxy-dibenzodiazepinones useful as hepatitis c virus inhibitors |
| FR2913017A1 (fr) | 2007-02-23 | 2008-08-29 | Cerep Sa | Derives de piperidine et piperazine comme agents anti-neoplasiques ou inhibiteurs de proliferation cellulaire |
| EP2150527B1 (en) | 2007-03-19 | 2011-01-19 | Council of Scientific & Industrial Research | Anthranilic acid derivative as anticancer agent and a process for the preparation thereof |
| WO2008135232A1 (en) * | 2007-05-02 | 2008-11-13 | Riccardo Cortese | Use and compositions of purine derivatives for the treatment of proliferative disorders |
| EP2148944A1 (en) | 2007-05-25 | 2010-02-03 | Burnham Institute for Medical Research | Inhibitors of thapsigargin-induced cell death |
| WO2009017838A2 (en) | 2007-08-01 | 2009-02-05 | Exelixis, Inc. | Combinations of jak-2 inhibitors and other agents |
| US20110124649A1 (en) | 2007-11-09 | 2011-05-26 | The Johns Hopkins University | Inhibitors of human methionine aminopeptidase 1 and methods of treating disorders |
| JP5562865B2 (ja) * | 2007-12-17 | 2014-07-30 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | Ｔｒｐｖ１のイミダゾロ−、オキサゾロ−、及びチアゾロピリミジン・モジュレーター |
| US8642660B2 (en) | 2007-12-21 | 2014-02-04 | The University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
| MX2011002263A (es) | 2008-09-10 | 2011-05-23 | Kalypsys Inc | Aminopirimidinas como inhibidores de receptores de histamina para el tratamiento de enfermedades. |
| EP2451813B1 (en) | 2009-07-08 | 2014-10-01 | Leo Pharma A/S | Heterocyclic compounds as jak receptor and protein tyrosine kinase inhibitors |
| US8993552B2 (en) * | 2009-09-04 | 2015-03-31 | The Regents Of The University Of Michigan | Compositions and methods for treatment of leukemia |
| GB201114212D0 (en) | 2011-08-18 | 2011-10-05 | Ucb Pharma Sa | Therapeutic agents |
| AR090037A1 (es) | 2011-11-15 | 2014-10-15 | Xention Ltd | Derivados de tieno y/o furo-pirimidinas y piridinas inhibidores de los canales de potasio |
| GB201217704D0 (en) * | 2012-10-03 | 2012-11-14 | Ucb Pharma Sa | Therapeutic agents |
| HK1220972A1 (zh) * | 2013-03-06 | 2017-05-19 | Bayer Pharma Aktiengesellschaft | 取代的噻唑并嘧啶 |
| WO2014164543A1 (en) | 2013-03-13 | 2014-10-09 | The Regents Of The University Of Michigan | Compositions comprising thienopyrimidine and thienopyridine compounds and methods of use thereof |
| US9212180B2 (en) * | 2013-06-12 | 2015-12-15 | The Regents Of The University Of Michigan | Menin-MLL inhibitors and methods of use thereof |
| LT3126352T (lt) | 2014-04-04 | 2019-01-10 | Syros Pharmaceuticals, Inc. | Nuo ciklino priklausomos kinazės 7 (cdk7) inhibitoriai |
| WO2015191701A1 (en) | 2014-06-10 | 2015-12-17 | The Trustees Of The University Of Pennsylvania | Scaffolds for inhibitors of menin-mll interactions |
| WO2016040330A1 (en) * | 2014-09-09 | 2016-03-17 | The Regents Of The University Of Michigan | Thienopyrimidine and thienopyridine compounds and methods of use thereof |
| AR104020A1 (es) | 2015-06-04 | 2017-06-21 | Kura Oncology Inc | Métodos y composiciones para inhibir la interacción de menina con proteínas mill |
| HK1246593A1 (zh) | 2015-06-04 | 2018-09-14 | Kura Oncology, Inc. | 用於抑制menin蛋白与mll蛋白的相互作用的方法及组合物 |
| KR20180103053A (ko) | 2015-12-22 | 2018-09-18 | 비타이 파마슈티컬즈, 인코포레이티드 | 메닌-mll 상호작용의 억제제 |
| EP4643952A3 (en) | 2016-01-26 | 2026-01-14 | Memorial Sloan Kettering Cancer Center | Targeting chromatin regulators for inhibiting leukemogenic gene expression in npm1 |
| BR112018068703B1 (pt) | 2016-03-16 | 2024-02-06 | Kura Oncology, Inc. | Inibidores substituídos de menin-mll e métodos de uso |
| KR102419524B1 (ko) | 2016-03-16 | 2022-07-08 | 쿠라 온콜로지, 인크. | 메닌-mll의 가교된 이환식 억제제 및 사용 방법 |
| WO2017192543A1 (en) | 2016-05-02 | 2017-11-09 | Regents Of The University Of Michigan | Piperidines as menin inhibitors |
| WO2017207387A1 (en) | 2016-05-31 | 2017-12-07 | Bayer Pharma Aktiengesellschaft | Spiro condensed azetidine derivatives as inhibitors of the menin-mml1 interaction |
| CA3024180A1 (en) | 2016-06-10 | 2017-12-14 | Vitae Pharmaceuticals, Inc. | Inhibitors of the menin-mll interaction |
| WO2018024602A1 (en) | 2016-08-04 | 2018-02-08 | Bayer Aktiengesellschaft | 2,7-diazaspiro[4.4]nonanes |
| WO2018050686A1 (en) | 2016-09-14 | 2018-03-22 | Janssen Pharmaceutica Nv | Spiro bicyclic inhibitors of menin-mll interaction |
| ES2966316T3 (es) | 2016-09-14 | 2024-04-19 | Janssen Pharmaceutica Nv | Inhibidores bicíclicos fusionados de interacción de MENIN-MLL |
| CN118359610A (zh) | 2016-09-16 | 2024-07-19 | 生命医药有限责任公司 | Menin-mll相互作用的抑制剂 |
-
2016
- 2016-03-15 AR ARP160100689A patent/AR104020A1/es active IP Right Grant
- 2016-03-15 TW TW105108013A patent/TWI703150B/zh active
- 2016-03-16 EA EA201792583A patent/EA035141B1/ru unknown
- 2016-03-16 ES ES16803881T patent/ES2902501T3/es active Active
- 2016-03-16 MY MYPI2017001731A patent/MY186712A/en unknown
- 2016-03-16 CN CN201680046005.5A patent/CN107922378A/zh active Pending
- 2016-03-16 CN CN202310178059.9A patent/CN116217581A/zh active Pending
- 2016-03-16 PT PT168038818T patent/PT3303317T/pt unknown
- 2016-03-16 KR KR1020187000217A patent/KR102626673B1/ko active Active
- 2016-03-16 JP JP2017558557A patent/JP6730321B2/ja active Active
- 2016-03-16 WO PCT/US2016/022717 patent/WO2016195776A1/en not_active Ceased
- 2016-03-16 PL PL16803881T patent/PL3303317T3/pl unknown
- 2016-03-16 MA MA043515A patent/MA43515A/fr unknown
- 2016-03-16 MX MX2017015467A patent/MX382545B/es unknown
- 2016-03-16 DK DK16803881.8T patent/DK3303317T3/da active
- 2016-03-16 EP EP21193636.4A patent/EP4006030A3/en active Pending
- 2016-03-16 AU AU2016270002A patent/AU2016270002B2/en active Active
- 2016-03-16 EP EP16803881.8A patent/EP3303317B1/en active Active
- 2016-03-16 PH PH1/2017/502188A patent/PH12017502188B1/en unknown
- 2016-03-16 CA CA2985053A patent/CA2985053C/en active Active
-
2017
- 2017-11-15 IL IL255701A patent/IL255701B/en active IP Right Grant
- 2017-11-20 ZA ZA2017/07848A patent/ZA201707848B/en unknown
- 2017-12-01 US US15/829,604 patent/US10077271B2/en active Active
-
2018
- 2018-06-21 US US16/014,996 patent/US10174041B2/en active Active
-
2025
- 2025-01-03 US US19/009,626 patent/US20250304589A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR104020A1 (es) | Métodos y composiciones para inhibir la interacción de menina con proteínas mill | |
| AR100438A1 (es) | Pirazolopiridinas y pirazolopirimidinas | |
| AR110922A1 (es) | Compuestos inhibidores del vih | |
| AR099824A1 (es) | Compuestos bicíclicos | |
| AR106301A1 (es) | Composiciones de pirrolpirimidina como inhibidores de quinasas | |
| AR087348A1 (es) | Indazoles, composiciones farmaceuticas que comprenden tales compuestos y su uso como medicamentos | |
| AR095464A1 (es) | Compuestos de heteroarilo y usos de los mismos | |
| AR114464A1 (es) | PROFÁRMACOS DE ANTAGONISTAS DE C5aR BICÍCLICOS FUSIONADOS | |
| AR115978A1 (es) | Compuesto con anillos fusionados | |
| AR101189A1 (es) | Heterociclos nitrogenados antiproliferativos y sus métodos de uso | |
| AR113965A1 (es) | Triazol azoles ciclohexil ácidos como antagonistas de lpa | |
| AR117978A1 (es) | Inhibidores de 15-pgdh | |
| AR094816A2 (es) | Compuestos antivirales | |
| AR100975A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| AR099913A1 (es) | Derivados de indolizina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| AR103182A1 (es) | Inmunomoduladores | |
| AR088293A1 (es) | Inhibidores de proteina cinasa | |
| AR093580A1 (es) | Inhibidores bmi-1 de pirimidina sustituidos | |
| AR100886A1 (es) | 3-amino-1,5,6,7-tetrahidro-4h-indol-4-onas | |
| AR094496A1 (es) | Compuestos tetracíclicos sustituidos con heterociclo y métodos de uso de los mismos para el tratamiento de enfermedades víricas | |
| AR118119A1 (es) | Compuestos de pirido-pirimidinilo y métodos de uso | |
| AR109487A1 (es) | Derivados de imidazo-2-il-piridin-2-ona como inhibidores de la unión de las proteínas bet | |
| AR100448A1 (es) | 5-(hetero)aril-piridazinonas y su uso como herbicida | |
| AR085352A1 (es) | Inhibidores macrociclicos de serina proteasa, sus composiciones farmaceuticas y su uso para tratar infecciones por hcv | |
| AR096424A1 (es) | Compuestos de 3,4-dihidro-2h-isoquinolin-1-ona y 2,3-dihidro-isoindol-1-ona |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |